Nitto Denko Avecia to buy Irvine and Avrio to expand offering

By Gareth Macdonald

- Last updated on GMT

iStock/TimArbaev
iStock/TimArbaev
Nucleic acid manufacturer Nitto Denko Avecia has agreed to buy Irvine Pharmaceutical Services and Avrio Biopharmaceuticals in deals designed to expand its production business.

Nitto said the deal – financial terms of which were not disclosed – will add Irvine’s analytical capabilities and Avrio’s contract drug and active pharmaceutical ingredient (API) production operations to its own nucleic acid manufacturing business.

Nitto president, Detlef Rethage, said: “We will work to realize the synergies between the three businesses by offering seamless outsourcing solutions for the benefit of our customers, including oligonucleotide drug substance, drug product, analytical development and related services​."

This was echoed by Assad Kazeminy, CEO of Irvine and Avrio, who said: “This combination provides an exciting expansion of breadth of capabilities and depth of expertise to support the growing needs of the pharmaceutical, biopharmaceutical and medical device industries​."

Avrio’s customer base includes Hemispherx​, which hired it to make its RNA-based chronic fatigue syndrome (CFS) therapy Ampligen (rintatolimod) In August. 

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars